By Sarah Collins | Market Realist – Fri, Apr 8, 2016 19:01 BST
Zimmer Biomet Holdings (ZBH) generates approximately 63% of its revenue from its reconstructive business segment. The segment consists of its leading portfolio of knee and hip implants and ~20% of its revenues from the SET (Surgical, Sports Medicine, Extremities, and Trauma) segment. The rest of the company’s revenue comes from its Dental Implants and Related Surgical Products segment and Spine & CMF (Craniomaxillofacial and Thoracic) category.
Wall Street analysts have estimated that the company’s 1Q16 revenues will be about $1.9 billion, which would represent a rise of around 65.4% on a YoY (year-over-year) basis compared to ~58.1% YoY revenue growth in the last quarter. It’s further estimated that the company will witness 58.8% YoY revenue growth in fiscal 2Q16.
